Pulmatrix, Inc.(PULM)Earnings, Financials & Key Ratios
PULM•NASDAQ
$1.30
$5M mkt cap·Price updated May 7, 2026
AboutPulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma, and in patients with cystic fibrosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.Show more
- Revenue$0-100.0%
- EBITDA-$5M+46.5%
- Net Income-$5M+46.0%
- EPS (Diluted)-1.41+46.2%
- ROE-80.93%-14.0%
PULM Key Insights
Pulmatrix, Inc. (PULM) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 1.2x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Weak momentum: RS Rating 3 (bottom 3%)
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
PULM Price & Volume
Pulmatrix, Inc. (PULM) stock price & volume — 10-year historical chart
Loading chart...
PULM Growth Metrics
Pulmatrix, Inc. (PULM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM46%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM46.36%
Return on Capital
10 Years-87.68%
5 Years-53.02%
3 Years-58.43%
Last Year-80.61%
PULM Peer Comparison
Pulmatrix, Inc. (PULM) competitors in Drug Delivery Technology Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 INVA | 1.93B | 22.80 | 6.91 | 18.52% | 118.91% | 46.47% | 0.23 | |
 PRAX | 9.63B | 333.28 | -24.72 | -100% | -43.02% | 0.00 | ||
 NKTR | 1.69B | 83.37 | -8.57 | -43.89% | -297.07% | -399.1% | 1.66 | |
 INSM | 22.62B | 104.80 | -16.35 | 66.73% | -210.54% | -168.36% | 1.04 | |
 ARWR | 10.92B | 77.95 | -6389.34 | 232.58% | -48.38% | -55.47% | 0.73 | |
 TPVG | 242.54M | 5.99 | 4.91 | 36.55% | -3.39% | 1.33 | ||
 MNKD | 1.1B | 3.55 | 177.50 | 22.23% | -6.63% | |||
 VRTX | 108.1B | 425.00 | 27.74 | 9.57% | 35.4% | 23.93% | 0.21 |
Compare PULM vs Peers
Pulmatrix, Inc. (PULM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PULM Income Statement
Pulmatrix, Inc. (PULM) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 335K | 153K | 7.91M | 12.63M | 5.17M | 6.07M | 7.3M | 7.81M | 0 |
| Revenue Growth % | -59.88% | -54.33% | 5069.93% | 59.72% | -59.09% | 17.45% | 20.21% | 6.96% | -100% |
| Cost of Goods Sold | 10.24M | 12.97M | 12.85M | 0 | 15.38M | 18.24M | 15.52M | 7.17M | 0 |
| COGS % of Revenue | 3057.61% | 8474.51% | 162.39% | - | 297.58% | 300.44% | 212.63% | 91.8% | - |
| Gross Profit | -9.91M▲ 0% | -12.81M▼ 29.3% | -4.93M▲ 61.5% | 12.63M▲ 356.0% | -10.21M▼ 180.8% | -12.17M▼ 19.2% | -8.22M▲ 32.5% | 640K▲ 107.8% | 0▼ 100.0% |
| Gross Margin % | -2957.61% | -8374.51% | -62.39% | 100% | -197.58% | -200.44% | -112.63% | 8.2% | - |
| Gross Profit Growth % | -6.34% | -29.32% | 61.48% | 356.01% | -180.84% | -19.15% | 32.45% | 107.79% | -100% |
| Operating Expenses | 7.57M | 7.59M | 15.76M | 22.5M | 9.95M | 6.78M | 6.52M | 10.4M | 5.17M |
| OpEx % of Revenue | 2258.81% | 4958.82% | 199.2% | 178.06% | 192.57% | 111.65% | 89.34% | 133.27% | - |
| Selling, General & Admin | 7.57M | 7.52M | 8.49M | 6.89M | 6.38M | 6.78M | 6.52M | 7.79M | 5.13M |
| SG&A % of Revenue | 2258.81% | 4913.73% | 107.32% | 54.51% | 123.37% | 111.65% | 89.34% | 99.73% | - |
| Research & Development | 10.24M | 12.97M | 12.85M | 15.61M | 15.38M | 18.24M | 15.52M | 7.17M | 38K |
| R&D % of Revenue | 3057.61% | 8474.51% | 162.39% | 123.55% | 297.58% | 300.44% | 212.63% | 91.8% | - |
| Other Operating Expenses | -10.24M | -12.9M | -5.58M | 0 | -11.8M | -18.24M | -15.52M | -4.55M | 0 |
| Operating Income | -17.48M▲ 0% | -20.4M▼ 16.7% | -20.69M▼ 1.4% | -9.86M▲ 52.3% | -20.17M▼ 104.5% | -18.95M▲ 6.0% | -14.74M▲ 22.2% | -9.76M▲ 33.8% | -5.17M▲ 47.1% |
| Operating Margin % | -5216.42% | -13333.33% | -261.59% | -78.06% | -390.15% | -312.09% | -201.97% | -125.07% | - |
| Operating Income Growth % | 29.72% | -16.74% | -1.43% | 52.34% | -104.49% | 6.05% | 22.2% | 33.77% | 47.06% |
| EBITDA | -17.23M | -20.17M | -20.51M | -9.65M | -20M | -18.79M | -14.61M | -9.66M | -5.17M |
| EBITDA Margin % | -5142.99% | -13182.35% | -259.29% | -76.36% | -386.88% | -309.42% | -200.14% | -123.71% | - |
| EBITDA Growth % | 30.01% | -17.06% | -1.69% | 52.96% | -107.3% | 6.07% | 22.25% | 33.88% | 46.47% |
| D&A (Non-Cash Add-back) | 246K | 231K | 182K | 215K | 169K | 162K | 134K | 106K | 0 |
| EBIT | -17.48M | -20.33M | -13.42M | -9.86M | -16.59M | -18.95M | -14.74M | -7.14M | 0 |
| Net Interest Income | -643K | -159K | 301K | 82K | 7K | 309K | 867K | 467K | 0 |
| Interest Income | 0 | 27K | 301K | 82K | 7K | 309K | 867K | 467K | 144K |
| Interest Expense | 643K | 186K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -581K | -163K | 96K | -9.45M | -4K | 111K | 619K | 204K | 7K |
| Pretax Income | -18.06M▲ 0% | -20.56M▼ 13.9% | -20.6M▼ 0.2% | -19.31M▲ 6.3% | -20.17M▼ 4.5% | -18.84M▲ 6.6% | -14.12M▲ 25.0% | -9.56M▲ 32.3% | -5.16M▲ 46.0% |
| Pretax Margin % | -5389.85% | -13439.87% | -260.38% | -152.83% | -390.23% | -310.26% | -193.49% | -122.46% | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -18.06M▲ 0% | -20.56M▼ 13.9% | -20.6M▼ 0.2% | -19.31M▲ 6.3% | -20.17M▼ 4.5% | -18.84M▲ 6.6% | -14.12M▲ 25.0% | -9.56M▲ 32.3% | -5.16M▲ 46.0% |
| Net Margin % | -5389.85% | -13439.87% | -260.38% | -152.83% | -390.23% | -310.26% | -193.49% | -122.46% | - |
| Net Income Growth % | 35.15% | -13.88% | -0.16% | 6.25% | -4.47% | 6.62% | 25.03% | 32.31% | 46% |
| Net Income (Continuing) | -18.06M | -20.56M | -20.6M | -19.31M | -20.17M | -18.84M | -14.12M | -9.56M | -5.16M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -186.42▲ 0% | -99.67▲ 46.5% | -24.37▲ 75.5% | -19.83▲ 18.6% | -8.63▲ 56.5% | -5.43▲ 37.1% | -3.87▲ 28.7% | -2.62▲ 32.3% | -1.41▲ 46.2% |
| EPS Growth % | 50.4% | 46.53% | 75.55% | 18.63% | 56.48% | 37.08% | 28.73% | 32.3% | 46.18% |
| EPS (Basic) | -186.42 | -99.67 | -24.37 | -19.83 | -8.63 | -5.43 | -3.87 | -2.62 | -1.41 |
| Diluted Shares Outstanding | 96.86K | 206.32K | 836.7K | 1.44M | 2.71M | 3.45M | 3.65M | 3.65M | 3.65M |
| Basic Shares Outstanding | 96.86K | 206.32K | 836.7K | 1.44M | 2.34M | 3.45M | 3.65M | 3.65M | 3.65M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
PULM Balance Sheet
Pulmatrix, Inc. (PULM) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 4.25M | 3.28M | 31.42M | 32.54M | 54.78M | 38.15M | 20.84M | 9.92M | 4.13M |
| Cash & Short-Term Investments | 3.55M | 2.56M | 23.44M | 31.66M | 53.84M | 35.63M | 19.17M | 9.52M | 4.09M |
| Cash Only | 3.55M | 2.56M | 23.44M | 31.66M | 53.84M | 35.63M | 19.17M | 9.52M | 4.09M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 1K | 0 | 7.2M | 84K | 67K | 1.3M | 928K | 0 | 0 |
| Days Sales Outstanding | 1.09 | - | 332.24 | 2.43 | 4.73 | 78.04 | 46.41 | - | - |
| Inventory | 0 | 0 | 0 | 667K | 0 | 153K | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | 3.06 | - | - | - |
| Other Current Assets | 71K | 55K | 253K | -593K | 0 | 166K | 372K | 180K | 41K |
| Total Non-Current Assets | 11.73M | 11.44M | 4.68M | 5.63M | 4.04M | 2.81M | 13.12M | 23K | 10K |
| Property, Plant & Equipment | 614K | 394K | 900K | 1.85M | 2.41M | 945K | 11.47M | 0 | 0 |
| Fixed Asset Turnover | 0.55x | 0.39x | 8.79x | 6.83x | 2.14x | 6.42x | 0.64x | - | - |
| Goodwill | 10.91M | 10.85M | 3.58M | 3.58M | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 204K | 204K | 204K | 0 | 1.63M | 1.47M | 1.47M | 10K | 0 |
| Other Non-Current Assets | 204K | 204K | 204K | 204K | 0 | 389K | 176K | 13K | 10K |
| Total Assets | 15.98M▲ 0% | 14.72M▼ 7.9% | 36.1M▲ 145.2% | 38.17M▲ 5.7% | 58.82M▲ 54.1% | 40.95M▼ 30.4% | 33.96M▼ 17.1% | 9.94M▼ 70.7% | 4.14M▼ 58.4% |
| Asset Turnover | 0.02x | 0.01x | 0.22x | 0.33x | 0.09x | 0.15x | 0.21x | 0.79x | - |
| Asset Growth % | -4.11% | -7.85% | 145.18% | 5.74% | 54.1% | -30.37% | -17.08% | -70.72% | -58.37% |
| Total Current Liabilities | 5.84M | 2.88M | 17.2M | 8.25M | 4.44M | 5.02M | 3.91M | 929K | 329K |
| Accounts Payable | 457K | 1.18M | 600K | 851K | 839K | 1.19M | 1.92M | 809K | 272K |
| Days Payables Outstanding | 16.28 | 33.3 | 17.05 | - | 19.91 | 23.77 | 45.04 | 41.21 | - |
| Short-Term Debt | 3.22M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 67K | 13.41M | 4.17M | 939K | 1.34M | 618K | 0 | 0 |
| Other Current Liabilities | 138K | 0 | 1.95M | 1.23M | 182K | 508K | 877K | 71K | 329K |
| Current Ratio | 0.73x | 1.14x | 1.83x | 3.94x | 12.33x | 7.60x | 5.33x | 10.68x | 12.55x |
| Quick Ratio | 0.73x | 1.14x | 1.83x | 3.86x | 12.33x | 7.57x | 5.33x | 10.68x | 12.55x |
| Cash Conversion Cycle | - | - | - | - | - | 57.33 | - | - | - |
| Total Non-Current Liabilities | 1K | 0 | 7.88M | 6.78M | 6.93M | 4.82M | 12.05M | 67K | 0 |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 608K | 857K | 0 | 8.33M | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 1K | 0 | 0 | 0 | 0 | 0 | 0 | 67K | 0 |
| Total Liabilities | 5.84M | 2.88M | 25.08M | 15.03M | 11.37M | 9.84M | 15.96M | 996K | 329K |
| Total Debt | 3.22M | 0 | 675K | 1.74M | 2.29M | 857K | 8.76M | 0 | 0 |
| Net Debt | -329K | -2.56M | -22.77M | -29.91M | -51.55M | -34.77M | -10.42M | -9.52M | -4.09M |
| Debt / Equity | 0.32x | - | 0.06x | 0.08x | 0.05x | 0.03x | 0.49x | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -27.18x | -109.68x | - | - | - | - | - | - | - |
| Total Equity | 10.14M▲ 0% | 11.84M▲ 16.8% | 11.02M▼ 7.0% | 23.14M▲ 110.0% | 47.45M▲ 105.1% | 31.11M▼ 34.4% | 18M▼ 42.2% | 8.95M▼ 50.3% | 3.81M▼ 57.4% |
| Equity Growth % | 15.71% | 16.84% | -6.97% | 109.99% | 105.06% | -34.44% | -42.16% | -50.28% | -57.42% |
| Book Value per Share | 104.66 | 57.41 | 13.17 | 16.09 | 17.52 | 9.02 | 4.93 | 2.45 | 1.04 |
| Total Shareholders' Equity | 10.14M | 11.84M | 11.02M | 23.14M | 47.45M | 31.11M | 18M | 8.95M | 3.81M |
| Common Stock | 2K | 0 | 2K | 4K | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | -174M | -194.56M | -215.16M | -234.47M | -254.64M | -273.48M | -287.6M | -297.16M | -302.32M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -2.87M | -2.12M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PULM Cash Flow Statement
Pulmatrix, Inc. (PULM) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -14.48M | -16.76M | 3.23M | -12.48M | -19.73M | -19.36M | -15.98M | -10.72M | -5.43M |
| Operating CF Margin % | -4321.49% | -10954.9% | 40.83% | -98.8% | -381.64% | -318.83% | -219.03% | -137.28% | - |
| Operating CF Growth % | -9.32% | -15.78% | 119.27% | -486.47% | -58.03% | 1.88% | 17.42% | 32.96% | 49.3% |
| Net Income | -18.06M | -20.56M | -20.6M | -19.31M | -20.17M | -18.84M | -14.12M | -9.56M | -5.16M |
| Depreciation & Amortization | 246K | 231K | 765K | 1.04M | 1.24M | 1.54M | 1.48M | 435K | 0 |
| Stock-Based Compensation | 2.82M | 2.97M | 2.07M | 1.16M | 1.16M | 1.11M | 954K | 511K | 25K |
| Deferred Taxes | -34K | 76K | 0 | 0 | 0 | -4.92M | 0 | 0 | 0 |
| Other Non-Cash Items | 204K | 38K | 7.27M | 9.29M | 3.58M | 4.92M | 8K | 2.69M | -296K |
| Working Capital Changes | 345K | 484K | 13.73M | -4.67M | -5.53M | -3.18M | -4.3M | -4.79M | 0 |
| Change in Receivables | 0 | 0 | -7.2M | 7.12M | 17K | -1.23M | 370K | 928K | 0 |
| Change in Inventory | 0 | 0 | 220K | -1.13M | -2.07M | 0 | 0 | 0 | 0 |
| Change in Payables | -290K | 726K | -583K | 300K | -149K | 511K | 727K | -1.11M | -537K |
| Cash from Investing | -74K | -19K | -58K | -281K | -144K | -86K | -676K | -398K | 0 |
| Capital Expenditures | -74K | -19K | -58K | -281K | -144K | -86K | -676K | -398K | 0 |
| CapEx % of Revenue | 22.09% | 12.42% | 0.73% | 2.22% | 2.79% | 1.42% | 9.26% | 5.1% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 13.92M | 15.79M | 17.7M | 20.98M | 43.48M | 1.23M | 53K | 0 | 0 |
| Debt Issued (Net) | -2.69M | -3.5M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 53K | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | -3.2M | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 304K | 0 | 160K | 13.67M | 3.4M | 0 | 0 | 0 | 0 |
| Net Change in Cash | -632K▲ 0% | -987K▼ 56.2% | 20.88M▲ 2215.2% | 8.22M▼ 60.6% | 23.6M▲ 187.3% | -18.21M▼ 177.2% | -16.61M▲ 8.8% | -11.11M▲ 33.1% | -5.43M▲ 51.1% |
| Free Cash Flow | -14.55M▲ 0% | -16.78M▼ 15.3% | 3.17M▲ 118.9% | -12.76M▼ 502.4% | -19.87M▼ 55.7% | -19.44M▲ 2.2% | -16.66M▲ 14.3% | -11.11M▲ 33.3% | -5.43M▲ 51.1% |
| FCF Margin % | -4343.58% | -10967.32% | 40.1% | -101.03% | -384.43% | -320.24% | -228.3% | -142.38% | - |
| FCF Growth % | -6.23% | -15.32% | 118.9% | -502.4% | -55.68% | 2.16% | 14.3% | 33.29% | 51.12% |
| FCF per Share | -150.23 | -81.33 | 3.79 | -8.88 | -7.34 | -5.64 | -4.56 | -3.04 | -1.49 |
| FCF Conversion (FCF/Net Income) | 0.80x | 0.82x | -0.16x | 0.65x | 0.98x | 1.03x | 1.13x | 1.12x | 1.05x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PULM Key Ratios
Pulmatrix, Inc. (PULM) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -134.61% | -191.09% | -187.1% | -180.17% | -113.05% | -57.15% | -47.95% | -57.51% | -70.96% | -80.93% |
| Return on Invested Capital (ROIC) | -121.07% | -129.83% | -160.3% | - | - | - | - | -564.61% | -209.09% | - |
| Gross Margin | -1115.81% | -2957.61% | -8374.51% | -62.39% | 100% | -197.58% | -200.44% | -112.63% | 8.2% | - |
| Net Margin | -3334.49% | -5389.85% | -13439.87% | -260.38% | -152.83% | -390.23% | -310.26% | -193.49% | -122.46% | - |
| Debt / Equity | 0.66x | 0.32x | - | 0.06x | 0.08x | 0.05x | 0.03x | 0.49x | - | - |
| Interest Coverage | -28.22x | -27.18x | -109.68x | - | - | - | - | - | - | - |
| FCF Conversion | 0.48x | 0.80x | 0.82x | -0.16x | 0.65x | 0.98x | 1.03x | 1.13x | 1.12x | 1.05x |
| Revenue Growth | -30.47% | -59.88% | -54.33% | 5069.93% | 59.72% | -59.09% | 17.45% | 20.21% | 6.96% | -100% |
PULM Frequently Asked Questions
Pulmatrix, Inc. (PULM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Pulmatrix, Inc. (PULM) saw revenue decline by 100.0% over the past year.
Pulmatrix, Inc. (PULM) reported a net loss of $5.2M for fiscal year 2025.
Dividend & Returns
Pulmatrix, Inc. (PULM) has a return on equity (ROE) of -80.9%. Negative ROE indicates the company is unprofitable.
Pulmatrix, Inc. (PULM) had negative free cash flow of $5.4M in fiscal year 2025, likely due to heavy capital investments.
Explore More PULM
Pulmatrix, Inc. (PULM) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates